Super exciting time to be in #t1d
Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash - https://t.co/8n6zVpMrYS
The markets are changing rapidly, tech is advancing fast, & we're all wondering what will be the next trends in #lifescience#investments. Come & join us, to hear from top #Healthcare#investors@Anglonordic - https://t.co/LcJk92RqOZ
A big thank you to everyone who made #BioTrinity a success including all our sponsors, speakers, exhibitors, suppliers and partners, the @OBN_UK events team, and of course to all the delegates who attended the physical event over the last two days.
Nara Daubeney, COO/Co-Founder of @phaimpharma talking about alternatives for autoimmune diseases such as type 1 diabetes at #BioTrinity. What is the relevance for #RareDiseases? AIM therapy can potentially reset the balance for many autoimmune diseases.
#biotrinity2016@BRAINCURES: '@OBN_UK@biotrinity 2022: Catalysing Growth in the Life Sciences Industry Company w/ presentations from
Vacmedix
Grey Wolf Therapeutics
Kargenera
Argonaut
Cumulus Oncology
Epsilogen
Antikorโฆ, see more https://t.co/4uu5RBCCEq
Thank you @phaimpharma, @FineTreatment, and Prismea for introducing yourselves at this evening's @OBN_UK Science Social. Really interesting quickfire presentations!
Find out more about these companies below:
https://t.co/ICjv8HJJ0E
https://t.co/4Lj4t0mWRG
https://t.co/AmE8WNsgFP
OBN would like to welcome another couple of new Members today - we look forward to working with you and seeing you at our events soon @phaimpharma and @intellin_